Chlamydia pneumoniae Hijacks a Host Autoregulatory IL-1β Loop to Drive Foam Cell Formation and Accelerate Atherosclerosis.

[1]  P. Shah,et al.  Chlamydia and Lipids Engage a Common Signaling Pathway That Promotes Atherogenesis. , 2018, Journal of the American College of Cardiology.

[2]  S. Hiller,et al.  The Gasdermin‐D pore acts as a conduit for IL‐1β secretion in mice , 2018, European journal of immunology.

[3]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[4]  J. Kearney,et al.  The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1β transcription and activate the NLRP3 inflammasome , 2017, The Journal of Biological Chemistry.

[5]  Minal Mulye,et al.  Manipulation of Host Cholesterol by Obligate Intracellular Bacteria , 2017, Front. Cell. Infect. Microbiol..

[6]  R. Gottlieb,et al.  Ogg1-Dependent DNA Repair Regulates NLRP3 Inflammasome and Prevents Atherosclerosis. , 2016, Circulation research.

[7]  V. Nizet,et al.  IL-1β is an innate immune sensor of microbial proteolysis , 2016, Science Immunology.

[8]  P. Eriksson,et al.  NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis , 2016, Journal of the American Heart Association.

[9]  P. Ridker,et al.  Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. , 2016, Circulation research.

[10]  K. Bornfeldt,et al.  Macrophage Phenotype and Function in Different Stages of Atherosclerosis. , 2016, Circulation research.

[11]  M. Cuchel,et al.  ABCA1 and Inflammation: From Animal Models to Humans. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[12]  E. Latz,et al.  The inflammasomes and autoinflammatory syndromes. , 2015, Annual review of pathology.

[13]  Xi-Long Zheng,et al.  Chlamydia pneumoniae negatively regulates ABCA1 expression via TLR2-Nuclear factor-kappa B and miR-33 pathways in THP-1 macrophage-derived foam cells. , 2014, Atherosclerosis.

[14]  Sarah Parish,et al.  Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.

[15]  N. Sinha,et al.  Pathogenicity of Mycobacterium tuberculosis Is Expressed by Regulating Metabolic Thresholds of the Host Macrophage , 2014, PLoS pathogens.

[16]  E. Verdin,et al.  Ketone bodies as signaling metabolites , 2014, Trends in Endocrinology & Metabolism.

[17]  Huidong Shi,et al.  Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. , 2014, Immunity.

[18]  Christine E. Becker,et al.  CD36 coordinates NLRP3 inflammasome activation by facilitating the intracellular nucleation from soluble to particulate ligands in sterile inflammation , 2013, Nature Immunology.

[19]  A. Jefferson,et al.  Nicotinic Acid Receptor GPR109A Is Down-Regulated in Human Macrophage-Derived Foam Cells , 2013, Heart.

[20]  A. Jefferson,et al.  167 NICOTINIC ACID RECEPTOR GPR109A IS DOWN-REGULATED IN HUMAN MACROPHAGE-DERIVED FOAM CELLS , 2013, Heart.

[21]  M. Landray,et al.  HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment , 2013, European heart journal.

[22]  P. Verma,et al.  Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype. , 2012, Cell host & microbe.

[23]  T. Crother,et al.  Innate immune responses to Chlamydia pneumoniae infection: role of TLRs, NLRs, and the inflammasome. , 2012, Microbes and infection.

[24]  R. Judd,et al.  Effects of high fat diet on GPR109A and GPR81 gene expression. , 2012, Biochemical and biophysical research communications.

[25]  J. Gage,et al.  Caspase-1 deficiency decreases atherosclerosis in apolipoprotein E-null mice. , 2012, The Canadian journal of cardiology.

[26]  D. Greaves,et al.  Anti-Inflammatory Effects of Nicotinic Acid in Human Monocytes Are Mediated by GPR109A Dependent Mechanisms , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[27]  B. Chaitman,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[28]  P. Edwards,et al.  ATP binding cassette transporter G1 (ABCG1) is an intracellular sterol transporter , 2011, Proceedings of the National Academy of Sciences.

[29]  M. Rosenfeld,et al.  Pathogens and atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis , 2011, Thrombosis and Haemostasis.

[30]  E. Latz,et al.  NLRP3 inflammasomes link inflammation and metabolic disease. , 2011, Trends in immunology.

[31]  Moshe Arditi,et al.  Caspase-1 Dependent IL-1β Secretion Is Critical for Host Defense in a Mouse Model of Chlamydia pneumoniae Lung Infection , 2011, PloS one.

[32]  K. Moore,et al.  Macrophages in the Pathogenesis of Atherosclerosis , 2011, Cell.

[33]  J. Tschopp,et al.  Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome , 2011, Cell Death and Disease.

[34]  S. Offermanns,et al.  Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. , 2011, The Journal of clinical investigation.

[35]  Shuang Chen,et al.  IL-17A Is Proatherogenic in High-Fat Diet-Induced and Chlamydia pneumoniae Infection-Accelerated Atherosclerosis in Mice , 2010, The Journal of Immunology.

[36]  E. Lien,et al.  Inflammation and Fibrosis during Chlamydia pneumoniae Infection Is Regulated by IL-1 and the NLRP3/ASC Inflammasome , 2010, The Journal of Immunology.

[37]  M. Elkind.  Infectious burden: a new risk factor and treatment target for atherosclerosis. , 2010, Infectious disorders drug targets.

[38]  G. Cook,et al.  The NLRP3 inflammasome, a target for therapy in diverse disease states , 2010, European journal of immunology.

[39]  K. Moore,et al.  NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease , 2010, Nature.

[40]  Shuiping Zhao,et al.  Niacin Promotes Cholesterol Efflux through Stimulation of the PPARγ-LXRα-ABCA1 Pathway in 3T3-L1 Adipocytes , 2009, Pharmacology.

[41]  P. Eriksson,et al.  A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta:interleukin-1 receptor antagonist balance in atherosclerosis. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[42]  C. Eder.  Mechanisms of interleukin-1beta release. , 2009, Immunobiology.

[43]  Shuang Chen,et al.  Chlamydia pneumoniae-Induced Foam Cell Formation Requires MyD88-Dependent and -Independent Signaling and Is Reciprocally Modulated by Liver X Receptor Activation1 , 2008, The Journal of Immunology.

[44]  P. Shah,et al.  TLR/MyD88 and Liver X Receptor α Signaling Pathways Reciprocally Control Chlamydia pneumoniae-Induced Acceleration of Atherosclerosis1 , 2008, The Journal of Immunology.

[45]  A. Tall,et al.  Increased Inflammatory Gene Expression in ABC Transporter–Deficient Macrophages: Free Cholesterol Accumulation, Increased Signaling via Toll-Like Receptors, and Neutrophil Infiltration of Atherosclerotic Lesions , 2008, Circulation.

[46]  M. Willingham,et al.  Increased Cellular Free Cholesterol in Macrophage-specific Abca1 Knock-out Mice Enhances Pro-inflammatory Response of Macrophages* , 2008, Journal of Biological Chemistry.

[47]  J. Guyton.  Niacin in cardiovascular prevention: mechanisms, efficacy, and safety , 2007, Current opinion in lipidology.

[48]  Nanping Wang,et al.  ROS and NF-κB but not LXR mediate IL-1β signaling for the downregulation of ATP-binding cassette transporter A1 , 2007 .

[49]  J. Heinecke,et al.  ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. , 2005, Physiological reviews.

[50]  D. Connolly,et al.  (d)-β-Hydroxybutyrate Inhibits Adipocyte Lipolysis via the Nicotinic Acid Receptor PUMA-G* , 2005, Journal of Biological Chemistry.

[51]  P. Parnet,et al.  ATP binding cassette transporter ABC1 is required for the release of interleukin‐1β by P2X7‐stimulated and lipopolysaccharide‐primed mouse Schwann cells , 2005, Glia.

[52]  S. Akira,et al.  Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[53]  G. Cheng,et al.  Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. , 2003, Molecular cell.

[54]  S. Tunaru,et al.  PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect , 2003, Nature Medicine.

[55]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[56]  A. von Eckardstein,et al.  The ATP binding cassette transporter A1 contributes to the secretion of interleukin 1beta from macrophages but not from monocytes. , 2002, Biochemical and biophysical research communications.

[57]  M. Fishbein,et al.  Toll-Like Receptor-4 Is Expressed by Macrophages in Murine and Human Lipid-Rich Atherosclerotic Plaques and Upregulated by Oxidized LDL , 2001, Circulation.

[58]  H. Brewer,et al.  Regulation and intracellular trafficking of the ABCA1 transporter. , 2001, Journal of lipid research.

[59]  H. Brewer,et al.  Cellular Localization and Trafficking of the Human ABCA1 Transporter* 210 , 2001, The Journal of Biological Chemistry.

[60]  J. Arnal,et al.  Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. , 1998, Circulation.

[61]  A Rubartelli,et al.  Interleukin-1beta secretion is impaired by inhibitors of the Atp binding cassette transporter, ABC1. , 1997, Blood.

[62]  B. Verrier,et al.  ABC1, an ATP Binding Cassette Transporter Required for Phagocytosis of Apoptotic Cells, Generates a Regulated Anion Flux after Expression in Xenopus laevis Oocytes* , 1997, The Journal of Biological Chemistry.

[63]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[64]  M. He,et al.  OxLDL-induced IL-1beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation , 2013, Inflammation Research.

[65]  L. Campbell,et al.  Chlamydia pneumoniae — an infectious risk factor for atherosclerosis? , 2004, Nature Reviews Microbiology.